Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
12
×
boston blog main
12
×
eli lilly
12
×
life sciences
national blog main
boston top stories
national top stories
san francisco blog main
clinical trials
indiana blog main
indiana top stories
san francisco top stories
fda
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
national
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
deals
novartis
startups
teva pharmaceutical
alzheimer's disease
amgen
cancer immunotherapy
europe blog main
What
drug
12
×
fda
approval
bio
companies
new
roundup
medicines
won
cancer
migraine
alzheimer’s
biotech
blueprint
class
decades
designed
latest
nash
news
pharmaceutical
price
prices
research
ret
therapies
treatment
week
year
acquisitions
acute
address
addresses
alkermes
amgen
annual
antipsychotic
approved
approves
arguments
Language
unset
Current search:
drug
×
biotech
×
" boston blog main "
×
" eli lilly "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines